Trial Profile
Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Motexafin gadolinium (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pharmacyclics
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2005 New trial record.